A specific antidote for dabigatran: functional and structural characterization

Felix Schiele(Boehringer Ingelheim (Germany)), Tobias Litzenburger(Boehringer Ingelheim (Germany)), Eliud Sepulveda(Boehringer Ingelheim (United States)), Keith A. Canada(Merck & Co., Inc., Rahway, NJ, USA (United States)), Herbert Nar(Boehringer Ingelheim (Germany)), Joanne van Ryn(Boehringer Ingelheim (Brazil)), John E. Park, Corey Newsome(Boehringer Ingelheim (United States))
DORA PSI (Paul Scherrer Institute)
January 1, 2013
Cited by 0

Related Papers

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
|New England Journal of Medicine|2017|1.1k
A specific antidote for dabigatran: functional and structural characterization
|Blood|2013|562
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454
Biophysics in drug discovery: impact, challenges and opportunities
|Nature Reviews Drug Discovery|2016|383